80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]呂美玲,賴麗萍,呂冬梅,等.干擾MS4A8對苦參堿抑制胃癌細(xì)胞生長的影響[J].福建醫(yī)藥雜志,2023,45(05):98-102.
點(diǎn)擊復(fù)制

干擾MS4A8對苦參堿抑制胃癌細(xì)胞生長的影響()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期數(shù):
2023年05期
頁碼:
98-102
欄目:
基礎(chǔ)研究
出版日期:
2023-10-15

文章信息/Info

文章編號:
1002-2600(2023)05-0098-05
作者:
呂美玲; 賴麗萍1; 呂冬梅; 黃智鋒; 陳水鈁
福建省廈門市中醫(yī)院藥學(xué)部(廈門 361000)
關(guān)鍵詞:
胃癌;  苦參堿;  MS4A8;  P13K-Akt-mTOR信號通路;  MAPKs信號通路;  增殖;  凋亡
分類號:
R735.2
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討干擾MS4A8對苦參堿抑制胃癌細(xì)胞生長的影響。方法 構(gòu)建干擾MS4A8細(xì)胞株,將所有細(xì)胞分為對照組、苦參堿組、苦參堿+shMS4A8組。采用CCK-8法檢測各組細(xì)胞的增殖活性,細(xì)胞克隆實(shí)驗(yàn)檢測細(xì)胞克隆形成,流式細(xì)胞儀檢測各組細(xì)胞的凋亡情況,Western blot檢測各組細(xì)胞中P13K-Akt-mTOR信號通路相關(guān)蛋白[磷酸化細(xì)胞外調(diào)節(jié)蛋白激酶(p-ERK)、磷酸化氨基未端蛋白激酶(p-JNK)、磷酸化P38絲裂原活化蛋白酶(p-p38)]和MAPKs信號通路相關(guān)蛋白[胞內(nèi)磷脂酰肌醇激酶(PI3K)、磷酸化蛋白激酶B(p-Akt)、雷帕霉素靶蛋白(mTOR)]表達(dá)情況。結(jié)果 與對照組相比,苦參堿組細(xì)胞增殖率降低(LSD-t=6.93,P=0.045); 與苦參堿組相比,苦參堿+shMS4A8組的細(xì)胞增殖率更低(LSD-t=6.34,P=0.005)。與對照組相比,苦參堿組AGS細(xì)胞克隆數(shù)明顯減少(LSD-t=3.33,P= 0.045); 與苦參堿組相比,苦參堿+shMS4A8組的細(xì)胞克隆數(shù)更少(LSD-t=3.03,P=0.005)。與對照組相比,苦參堿組AGS細(xì)胞凋亡率增加(LSD-t=-7.76,P=0.0004); 與苦參堿組相比,苦參堿+shMS4A8組的細(xì)胞凋亡率更高(LSD-t=-16.66,P=0.0001)。與對照組相比,苦參堿組p-ERK、p-JNK、p-p38、PI3K、p-Akt、mTOR的相對表達(dá)量均減少(LSD-t=5.95,P=0.0117; LSD-t=9.43,P=0.0027; LSD-t=11.41,P=0.0016; LSD-t=27.10,P=0.0002; LSD-t=34.75,P=0.0001; LSD-t=13.89,P=0.0010); 與苦參堿組相比,苦參堿+shMS4A8組p-ERK、p-JNK、p-p38、PI3K、p-Akt、mTOR的相對表達(dá)量均更少(LSD-t=5.41,P=0.0115; LSD-t=7.08,P=0.0044; LSD-t=4.11,P=0.0284; LSD-t=10.18,P=0.0011; LSD-t=4.22,P=0.0262; LSD-t=10.26,P=0.0011)。結(jié)論 干擾MS4A8可通過P13K-Akt-mTOR和MAPKs信號通路增強(qiáng)苦參堿抑制細(xì)胞增殖和細(xì)胞克隆數(shù)形成,增加細(xì)胞凋亡。

參考文獻(xiàn)/References:

[1] Ajani J A, D'Amico T A, Bentrem D J, et al.Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(2):167-192.
[2] Hu H F,Wang Z,Tang W L,et al.Effects of Sophora flavescens aiton and the absorbed bioactive metabolite matrine individually and in combination with 5-fluorouracil on proliferation and apoptosis of gastric cancer cells in nude mice[J].Front Pharmacol,2022,13:1047507.
[3] 鄢傳經(jīng),胡清林,嚴(yán)海,等.共表達(dá)網(wǎng)絡(luò)分析揭示新型生物標(biāo)志物在胃腺癌患者生存預(yù)后中的應(yīng)用價(jià)值[J].胃腸病學(xué)和肝病學(xué)雜志,2019,28(6):637-643.
[4] Dodson M,Castro-Portuguez R,Zhang D D.NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis[J].Redox Biol,2019,23:101-107.
[5] Chang Y W,Chen M W,Chiu C F,et al.Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-kappaB signaling in cervical cancer[J].Ann Surg Oncol,2014,21(Suppl 4):s687-s695.
[6] Li C,Zhang Y,Liu J,et al.Mitochondrial DNA stress tri-ggers autophagy-dependent ferroptotic death[J].Autophagy, 2021,17(4):948-960.
[7] Bai Y,Meng L,Han L,et al.Lipid storage and lipophagy regulates ferroptosis[J].Biochem Biophys Res Commun, 2019,508(4):997-1003.
[8] He L,Deng H Y,C Wang X.Decreased expression of MS4A12 inhibits differentiation and predicts early stage survival in colon cancer[J].Neoplasma,2017,64(1):65-73.
[9] Li S,Zhan Y L,Xie Y W,et al.The impact of icariside Ⅱ on human prostate cancer cell proliferation,mobility,and autophagy via pi3k-akt-mtor signaling pathway[J].Drug Des Devel Ther,2020,14:4169-4178.
[10] Roudsari N M,Lashgari N A,Momtaz S,et al.Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention[J].Pharmaceutics,2021,13(8):3-15.
[11] Liu S Y,Li X,Lin Z M,et al.SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis[J].Cancer Lett,2018,416:11-23.
[12] Peng Y,Wang Y Y,Zhou C,et al.PI3K/Akt/mTOR Path-way and Its Role in Cancer Therapeutics: Are We Making Headway?[J].Front Oncol,2022,12:819128.
[13] Tong W,Chen X,Song X,et al.Resveratrol inhibits LPS-induced inflammation through suppressing the signaling cascades of TLR4-NF-kappaB/MAPKs/IRF3[J].Exp Ther Med,2020,19(3):1824-1834.
[14] Osaki L H,Gama P.MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation[J].Int J Mol Sci,2013,14(5):10143-10161.

相似文獻(xiàn)/References:

[1]楊蔡江.胃癌癌組織中p27與cyclinD1的表達(dá)及臨床意義[J].福建醫(yī)藥雜志,2017,39(5):50.
[2]陳國平 陳劍明.多項(xiàng)腫瘤標(biāo)記物在胃癌診斷中的篩選及應(yīng)用價(jià)值[J].福建醫(yī)藥雜志,2019,41(02):4.
　CHEN Guoping,CHEN Jianming..Value of screening and application of multiple combined tumor markers in the diagnosis of gastric cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(05):4.
[3]趙 珅 范南峰 李 惠 劉 捷 俞嘉青 林榕波.阿帕替尼聯(lián)合紫杉醇化療方案治療紫杉醇耐藥的晚期胃癌的臨床研究[J].福建醫(yī)藥雜志,2020,42(01):16.
　ZHAO Shen,FAN Nanfeng,LI Hui,et al.Clinical study of apatinib combined with paclitaxel chemotherapy in the treatment of paclitaxel-resistant advanced gastric cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(05):16.
[4]沈惠群,沈松菲.5-Aza-CdR對胃癌中SOX17基因表達(dá)的影響[J].福建醫(yī)藥雜志,2024,46(01):24.[doi:10.20148/j.fmj.2024.01.007]

備注/Memo

備注/Memo:
基金項(xiàng)目:2021年度廈門市醫(yī)療衛(wèi)生指導(dǎo)性項(xiàng)目(3502Z20214ZD1162)
1 通信作者,Email:[email protected]
更新日期/Last Update: 2023-10-15